Aegis Capital Corp. in an IPO of Signal Genetics
Blank Rome represented Aegis Capital Corp. in an $8.5 million IPO of Signal Genetics, Inc., an emerging commercial stage, molecular diagnostic company focused on providing innovative diagnostic services that help physicians make decisions concerning the care of their patients suffering from cancer. The transaction closed on June 23, 2014.